12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kynamro mipomersen regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 that efficacy and safety data for Kynamro mipomersen from the Genzyme Corp. unit of Sanofi support approval to treat patients with homozygous familial hypercholesterolemia (hoFH). Panelists were concerned about high discontinuation rates, modest efficacy...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >